OFFICIALS LEGISLATION INTEREST GROUPS PUBLIC STATEMENTS COMMITTEES VETOES

Food and Drug Administration Safety and Innovation Act

Floor Speech

Date: June 20, 2012
Location: Washington, DC
Issues: Health and Health Care

BREAK IN TRANSCRIPT

Mr. LANCE. Thank you, Mr. Chairman.

Mr. Speaker, such legislation will ensure that patients get improved access to innovative, lifesaving therapies and medical devices while protecting and creating U.S. jobs. The bill is critically important to New Jersey, where we have a high concentration of medical device, pharmaceutical, and life science employees.

I'm pleased that the conference report contains provisions important to streamline and modernize FDA regulations while promoting patient safety. Just as important, today's measure is fiscally responsible, reducing the deficit by $311 billion over the next 10 years according to the CBO.

I thank Chairman Upton, Chairman Pitts, Ranking Member Waxman, Ranking Member Pallone, and members of the Energy and Commerce Committee for working together in a bipartisan capacity on a final bill that protects patients and brings much needed certainty to the medical and biopharmaceutical industries. This is the way Congress should work.

BREAK IN TRANSCRIPT


Source
arrow_upward